Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
AZ “disappointment” at heart drug failure
October 5, 2016Research and Development AZ, AstraZeneca, trial failure
AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …
FDA warns that certain hepatitis C drugs can have serious side-effects
October 5, 2016Medical Communications, Research and Development FDA, hepatitis B, hepatitis C
The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
Mylan’s promised half-price EpiPen not available until year’s end
October 5, 2016Research and Development, Sales and Marketing Mylan, epipen
Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …
Roche granted breakthrough therapy designation by FDA
October 5, 2016Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy
Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …
Patients’ insulin pumps are revealed to be hackable by J&J
October 4, 2016Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin
Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …
Roche’s Alecensa receives second FDA Breakthrough Therapy Designation
October 4, 2016Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib
Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …
AstraZeneca’s wins major drug approval by NICE
October 4, 2016Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso
AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …
Sanofi’s dengue vaccine scores 11th worldwide approval in Singapore
October 4, 2016Sales and Marketing Sanofi, dengue, drug approval
Sanofi Pasteur, the vaccines unit of the wider French firm, has announced that its dengue vaccine Dengvaxia has secured market …
NICE and the CDF: Are they still up to scratch?
October 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE
Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
Merrimack Pharmaceuticals’ CEO resigns and workforce cut by nearly a quarter
October 3, 2016Sales and Marketing Gary Crocker, Merrimack Pharmaceuticals, Robert Mulroy
Merrimack Pharmaceuticals announced that they would cut away 22% of their workforce and their CEO, Robert Mulroy, would leave immediately …
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …
Regeneron’s Eylea fails combination study endpoint
October 3, 2016Research and Development, Sales and Marketing Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …
Novartis reveals impressive four year data upon Cosentyx
October 3, 2016Sales and Marketing Cosentyx, Novartis, psoriasis
Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …
GSK agrees to $20m settlement for Chinese bribery allegation
October 3, 2016Business Services, Sales and Marketing China, GSK, GlaxoSmithKline
GlaxoSmithKline has agreed to settle a bribery allegation in China with a payment of $20 million to the US Securities …
Meet SHL at 2016 PDA Universe of Pre-filled Syringes & Injection Devices
October 3, 2016Manufacturing and Production
At this year’s PDA Universe of Pre-filled Syringes & Injection Devices, SHL will be showcasing both new technologies and time-tested …
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Joanne Beckwith Joins the Clinical Trials Team at Woodley Equipment Company
September 30, 2016clinical research, clinical trials
Woodley Equipment Company Limited is pleased to announce Joanne Beckwith has joined Woodley’s Clinical Trials Division as Logistics Facilitator based at …
Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative
September 30, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
